A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
for
Prostate Cancer,
Location: Myrtle Beach SC, Charlottesville VA, Tampa FL,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: Male
Age: 18+
Code: NCT07005154
Phase2, Recruiting
Active & Responsive
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
for
Castration-Resistant Prostate Carcinoma,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: Male
Age: 0+
Code: NCT06145633
Phase2, Recruiting
Active & Responsive
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
for
Metastatic Castrate Resistant Prostate Cancer,
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: VA Office of Research and Development
Sex: Male
Age: 18+
Code: NCT04038502
Phase2, Recruiting
Active & ResponsiveNew
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
64Cu-GRIP B in Patients With Advanced Malignancies
for
Prostate Cancer, Renal Cancer, Urethral Cancer,
Location: San Francisco CA
Sponsor: Rahul Aggarwal
Sex: All
Age: 18+
Code: NCT05888532
Phase1, Phase2, Recruiting
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
for
Castration-Resistant Prostate Carcinoma,
Location: San Francisco CA
Sponsor: Vadim S Koshkin
Sex: All
Age: 18+
Code: NCT05113537
Phase1, Phase2, Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
for
Metastatic Castration-Resistant Prostate Cancer
Location: St Louis MO, Rochester MN, Omaha NE, Los Angeles CA,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT06531499
Phase1, Recruiting
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
for
Oligoprogressive, Castration-Resistant Prostate Cancer
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre
Sex: Male
Age: 18+
Code: NCT04838899
Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
for
Prostate Cancer,
Location: Providence RI, New Haven CT, Mineola NY,
Sponsor: Janux Therapeutics
Sex: Male
Age: 18 - 70+
Code: NCT05519449
Phase1, Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
for
Metastatic Castration-Resistant Prostate Cancer
Location: Boston MA, Miami FL, Tampa FL, Chicago IL, Omaha NE